Absci posts Q4 revenue $1.5M, net loss $25.2M; reveals AI antibody design breakthroughs, partners NVIDIA

Absci Corp

Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.
Cash of $279.9M; expects ~$120M net cash burn in 2022 (incl. ~$10.5M restricted cash).
Announced ML models predicting antibody affinity across 4 orders of magnitude and naturalness scoring.
Formed research collaboration with NVIDIA to scale in-silico drug discovery on A100 GPUs.
Entered Merck collaboration for Bionic Enzyme; projected 8 active programs in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.